OCT 01, 2019 11:03 AM PDT

Breast Cancer Drug Increases Survival for Prostate Cancer Patients

WRITTEN BY: Carmen Leitch

A clinical trial has shown that a drug used in the treatment of ovarian and breast cancer is better at treating advanced prostate cancer in some men than targeted hormone therapeutics that are currently in use. The study, called the PROfound trial (described in the video), compared the efficacy of olaparib, which is approved for use in breast cancer patients with BRCA mutations, with the drugs abiraterone and enzalutamide, which are hormone treatments used to target prostate cancer tumors carrying dysfunctional DNA repair genes. Olaparib delayed the progression of prostate cancer by about 66 percent in men carrying these faulty genes.

"Our clinical trial shows that olaparib, a pill without the side effects of chemotherapy, is able to target an Achilles' heel in cancer cells. Olaparib is able to kill cancer cells with faulty DNA repair genes while sparing normal cells," explained the co-leader of the trial, Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London.

Men with prostate cancer who had received hormone therapy to treat tumors carrying one of fifteen dysfunctional DNA repair genes in their cells were selected for this study. A gene called ATM, and the well-known genes associated with breast cancer BRCA1 and BRCA2 were some of those genes. For patients with genetic changes in those genes, the amount of time they had before their cancer progressed was lengthened by olaparib treatment; their profession-free survival time was extended from 3.6 months to 7.4 months. Olaparib treatment extended the median overall survival time to 18.5 months from 15 months with hormonal treatment.

This work confirms a study from earlier this year that determined olaparib could double progression-free survival in men with BRCA alterations in their prostate tumor cells.

"Our findings also have wider implications in showing that prostate cancer, like many other cancer types, is really a range of sub-types of disease identifiable by their different arrays of genetic faults. It's essential that we become smarter in the way we treat prostate cancer so that every man gets the treatment that will be of greatest benefit for them," added de Bono.

Wild type human prostate cells from an organoid  / Credit: National Institutes of Health

More follow-up will be needed for these patients to prove that olaparib is a better drug, the researchers noted. The drug also had higher rates of adverse impacts compared to the hormone therapies. About 8.5 percent of patients cannot tolerate the abiraterone or enzalutamide, while 16.4 percent of patients had to stop taking olaparib. The olaparib treatment also goes on for about twice as long.

This study has shown that there are subtypes of prostate cancer, just as there are with lung and breast cancer. It also demonstrates that assessing tumor cell genomes can provide important information that can help determine which treatment is best for a patient.

"This study is a powerful demonstration of the potential of precision medicine to transform the landscape for patients with the commonest of male cancers. I hope that within the next couple of years, olaparib will become the first precision medicine to become available as a standard treatment for men with prostate cancer," said de Bono.

Learn more about BRCA in different types of tumors from the video.


Sources: AAAS/Eurekalert! via Institute of Cancer Research

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
SEP 14, 2020
Cancer
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
SEP 14, 2020
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
It is often unknown whether a patient will respond to a treatment until it is in full swing. New research is attempting ...
SEP 14, 2020
Genetics & Genomics
Why Defects in One Gene Can Lead to Cancer in Kids
SEP 14, 2020
Why Defects in One Gene Can Lead to Cancer in Kids
While they may occur in adults, a rare, aggressive type of brain cancer called atypical teratoid rhabdoid tumors tend to ...
SEP 23, 2020
Immunology
Gene That Fuels Antibody Factories Discovered
SEP 23, 2020
Gene That Fuels Antibody Factories Discovered
Antibodies are Y-shaped proteins that play a central role in the immune system’s arsenal of germ-busting weapons. ...
SEP 28, 2020
Genetics & Genomics
Why Some Young, Healthy People Get Severe COVID-19
SEP 28, 2020
Why Some Young, Healthy People Get Severe COVID-19
Since the start of the pandemic, scientists have been trying to find out why some people get such severe illness from SA ...
NOV 03, 2020
Cell & Molecular Biology
The Connections Between Toxins, Genes, and Disease
NOV 03, 2020
The Connections Between Toxins, Genes, and Disease
We are exposed to a vast array of chemicals every day. Many are harmless or even important, like the air we breathe, wat ...
NOV 09, 2020
Genetics & Genomics
Potential Problems with Liquid Biopsies
NOV 09, 2020
Potential Problems with Liquid Biopsies
Liquid biopsies are tests that look for biomarkers in the blood, which can help inform the treatment of cancer. The tool ...
Loading Comments...